Business Ethics

A culture of integrity, accountability & transparency

On January 1, 2025, new UK-wide arrangements for the supply of medicines came into effect as set out in the Windsor Framework agreement. One of the impacts from the Windsor Framework is that all medicines placed on the UK market must be labelled “UK Only.”

Fresenius Kabi has completed a robust project in preparation for the implementation date and we can say that we have successfully implemented this change on all our licensed medicinal products.

Customers may still be supplied packs that do not contain “UK Only” that were manufactured and released to the UK prior to the implementation date. All packs that were manufactured and released from 1st January 2025 will be labelled as “UK Only”.

At Fresenius Kabi we care for the life of patients worldwide. To fulfil our commitment to benefit critically and chronically ill patients, collaborating with healthcare professionals, health care organisations and patient organisations is essential. We comply with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry. This Code includes requirements of how we may work with healthcare professionals, healthcare organisations and patient organisations and has introduced new requirements to ensure greater transparency in these areas.

Transparency is essential to building and maintaining confidence in us and our products.

HCP & HCO Annual Disclosure Reports

As a member of EFPIA and in accordance with ABPI Code requirements, Fresenius Kabi Limited and Calea UK Limited ensure that the nature and scope of any transfers of value with healthcare professionals and healthcare organisations are clear and transparent.

Visit www.disclosure.org.uk to see a full database of the payments we make to healthcare professionals and healthcare organisations in the UK. 

Fresenius Kabi Limited and Calea UK Limited Methodological Notes

2024 Methodological Notes for reporting - click here

2023 Methodological Notes for reporting - click here

2022 Methodological Notes for reporting - click here

2021 Methodological Notes for Reporting - click here

We welcome any questions or remarks at transparency@fresenius-kabi.com

Patient Organisations Funding and Support 

We believe that being transparent about our support for patient groups helps to build trust with our stakeholders.

2024 Patient and Patient Organisations Disclosure Report - click here

2023 Patient and Patient Organisations Disclosure Report - click here

2022 Patient and Patient Organisations Disclosure Report - During 2022 we did not provide support to patient groups - click here

2021 Patient and Patient Organisations Disclosure Report - click here

Improving patient outcomes in moderate RA - Implementing TA715 at Bedfordshire Hospitals NHS Foundation Trust

To read the executive summary for this project click here

Supporting the Rheumatology Service at University Hospitals Birmingham NHS Foundation Trust with Pharmacist Staff

To read the executive summary for this project click here

To read the summary of this project now that it is complete click here

The Trustees believe that good stewardship and the incorportation of environmental, social, and corporate governance (ESG) factors into their investment decision-making processes can have a material impact on the financial and non-financial performance of the Scheme's assets over the medium and longer term.

To read the full Engagement Policy Implementation Statement click here

This statement has been prepared in compliance with section 54 of the Modern Slavery Act 2015 to set out the steps that Fresenius Kabi UK has taken during its financial year ending in 2023 to prevent slavery and human trafficking from taking place in its business or any of its supply chain.
This statement has been approved by the UK Leadership Team on 28 June 2024.

To read the full Modern Slavery Statement click here

 

The Trustees of the Fresenius Health Care Group Pension Scheme (“the Scheme”) have drawn up this Statement of Investment Principles (“the Statement”) to comply with the requirements of the Pensions Act 1995 (“the Act”) and subsequent legislation. The statement is intended to affirm the investment principles that govern the Trustees’ decisions about the Scheme’s investments. 

In preparing this Statement the Trustees have consulted Fresenius Kabi Limited (“the Sponsor”) to ascertain whether there are any material issues that the Trustees should be aware of when setting the Scheme’s investment arrangements. The Trustees have also taken account of the Investment Governance Group Code of Best Practice for institutional investors, a voluntary code which has been endorsed by the UK government and the National Association of Pension Funds.

To read the full statement click here

To read the full Engagement Policy Implementation Statement for the Year Ended 31 December 2021 - Fresenius Health Care Group Pension Scheme click here

To read the full Statement of Investment Principles September 2020 - Fresenius Health Care Group Pension Scheme - click here

Gender Pay Gap Report 2024

Fresenius Kabi Limited is required by law to publish an annual gender pay gap report. This is our report for the snapshot date of 5 April 2024.

  • The mean gender pay gap for Fresenius Kabi Limited is 8.2%
  • The median gender pay gap for Fresenius Kabi Limited is -12.5%
  • The mean gender bonus gap for Fresenius Kabi Limited is 27.8%
  • The median gender bonus gap for Fresenius Kabi Limited is -0.8%
  • The proportion of male employees in Fresenius Kabi Limited receiving a bonus is 87.8% and the proportion of female employees receiving a bonus is 88.9%

Pay Quarters by Gender

Band A – Upper Quarter

  • Males 41.2%
  • Females 58.8%

Includes all employees whose standard hourly rate places them in the upper pay quarter

Band B – Upper Middle Quarter

  • Males 22.9%
  • Females 77.1%

Includes all employees whose standard hourly rate places them in the upper middle pay quarter

Band C – Lower Middle Quarter

  • Males 48.5%
  • Females 51.5%

Includes all employees whose standard hourly rate places them in the lower middle pay quarter

Band D – Lower Quarter

  • Male 41.7%
  • Females 58.3%

Includes all employees whose standard hourly rate places them in the lower pay quarter.

The figures set out above have been calculated using the standard methodologies used in the Equality Act 2010 (Gender Pay Gap Information) Regulations 2017.

Fresenius Kabi Limited is committed to the principle of equal opportunities and equal treatment for all employees, regardless of sex, race, religion or belief, age, marriage or civil partnership, pregnancy/maternity, sexual orientation, gender reassignment or disability. It has a clear policy of paying employees equally for the same or equivalent work, regardless of their sex (or any other characteristic set out above).

Fresenius Kabi Limited is therefore confident that its gender pay group does not stem from paying men and women differently for the same or equivalent work. Rather its gender pay gap is the result of the roles in which men and women work within the organisation and the salaries that these roles attract.

I, Mikko Tiitinen, Managing Director (UK and Ireland), Fresenius Kabi Limited. Confirm that the information in this statement is accurate.

To download the report click here

You can find our previous Gender Pay Gap reports using the links below:

2023 - Gender Pay Gap Report 2023

2022 - Gender Pay Gap Report 2022

2021 -  Gender Pay Gap Report 2021

2020 - Gender Pay Gap Report 2020

In accordance with UK legislations, Schedule 19 of Finance Act 2016, the company is publishing its tax strategy for the Year Ended 31st December 2022, which will be refreshed annually. We confirm that this strategy will apply to the following UK companies for all UK taxes:

  • Fresenius Kabi Limited 
  • Calea UK Limited 
  • FHC (Holdings) Limited
  • Fresenius Kabi Oncology plc
Approach to Tax Risk Management & Governance

We aim for our tax affairs to be compliant with UK tax legislation and the Board of Directors in the UK are committed to the delivery of tax compliance.
We employ the services of a professional tax advisor to prepare our Corporate Tax Computations and, Returns and to provide other services including tax technical updates and flagging new legislation to help reduce the risk of non-compliance. We also ensure that we employ appropriately qualified and experienced staff to prepare and submit relevant returns, for example VAT and PAYE.

Level of Tax Risk we are prepared to accept

Our appetite for tax risk is low and the UK Board of Directors sees compliance with tax legislation as key to managing our tax risk by using principals of reasonable.
Due to the size and complexity of the business there is an inherent degree of tax risk. We recognise that eliminating tax risk entirely is impossible, but we aim to manage our tax risk as far as practically possible.
In areas of uncertainty where tax risk arises from the complexity of tax legislation and differences in interpretation, we will seek appropriate external advice before engaging with HMRC.
Our approach is to aim to be compliant and understand our responsibilities with regard to tax and we will claim legitimate tax incentives, exemptions and reliefs offered by the UK Government to all tax payers.

Attitude towards Tax Planning

We will consider a range of tax outcomes based on the underlying commercial intention of any business activity or transaction that supports our business activities and the Group’s code of conduct, rather than looking for ways to aggressively avoid the payment of tax. We seek to balance the shareholders’ interest of managing business expenses, which include taxation, with ensuring that any arrangements comply with current UK tax legislation.
We have a responsibility to minimise our tax risk and our exposure to negative publicity through non-compliance.

Approach towards dealing with HMRC

We seek to ensure that our engagement with HMRC is professional, open and honest by having a co-operative and proactive working relationship with them. We also aim to undertake our filing requirements in a timely manner, by meeting relevant filing and payment deadlines for taxes that the company pays.

 

GB-NP-2500055 April 2025